The EGFR-Multiplex 1% AF cfDNA in Plasma is a state-of-the-art product designed to support the detection and analysis of critical EGFR mutations. These mutations are known driver mutations and are commonly implicated in severe cancers, such as lung and breast cancer. Understanding and detecting EGFR mutations is essential, especially for effective treatment and therapy planning for Non-Small Cell Lung Cancer (NSCLC).

The SensID EGFR-Multiplex 1% AF cfDNA in Plasma features an essential mix of mutations, including both TKI (tyrosine kinase inhibitor) sensitive and TKI resistant types. These specific mutations are directly relevant for determining targeted therapies and optimizing patient care. By offering a comprehensive panel of mutations, this product plays a crucial role in guiding clinical decisions.

Furthermore, the EGFR-Multiplex 1% AF cfDNA in Plasma is an invaluable tool for diagnostic laboratories and R&D departments. It serves as a robust positive standard in liquid biopsy assays, ensuring precise and accurate testing. The use of cfDNA from the Ashkenazim Son cell line as background material, along with human-tech plasma, enhances the reliability of the assays and simulates real clinical conditions. Researchers and developers can also leverage this product to validate and refine their EGFR diagnostic kits.

With its high-quality formulation, the EGFR-Multiplex 1% AF cfDNA in Plasma supports efficient assay development and enhances the reproducibility of results. Its reliability aids in the validation of new diagnostic tests, ensuring consistent and high-performance outcomes in clinical settings. Whether you are developing new assays or optimizing existing diagnostic tools, this product provides the necessary standardization for cutting-edge research and clinical advancements.